Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 61

Sort by

Sort Order Select

Journal Articles

CD49d Expression Is Included in a Revised 4-Factor Model Predicting Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Multi-Center Real-World Experience

Blood (2023) 142 (Supplement 1): 3281.

https://doi.org/10.1182/blood-2023-174897

Published: 2023

Journal Articles

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

Blood (2023) 142 (Supplement 1): 1905.

https://doi.org/10.1182/blood-2023-181597

Published: 2023

Journal Articles

MRD Monitoring By Euroclonality IGH Based NGS Approach Predicts Outcome in Follicular Lymphoma Patients Lacking a Conventional BCL2::IGH Marker: A Substudy from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial

Blood (2023) 142 (Supplement 1): 4373.

https://doi.org/10.1182/blood-2023-181813

Published: 2023

Journal Articles

A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial

Blood (2023) 142 (Supplement 1): 6544.

https://doi.org/10.1182/blood-2023-188454

Published: 2023

Journal Articles

Early-Stage Follicular Lymphoma: Learnings from the Final Analysis of the Multicenter Phase II FIL (Fondazione Italiana Linfomi) “Miro” Trial, Combining Local Radiotherapy and MRD-Driven Immunotherapy

Blood (2023) 142 (Supplement 1): 4399.

https://doi.org/10.1182/blood-2023-182946

Published: 2023

Journal Articles

Impact of Anti-Sars-Cov-2 Monoclonal Antibodies in the Management of Patients with Lymphoma and COVID19: A Retrospective Study

Giovanni Manfredi Assanto, Alice Di Rocco, Francesco Malfona, Marcello Capriata, Ilaria Del Giudice, Luigi Petrucci, Paola Girardi, Gianna Maria D'elia, Maurizio Martelli, Giuseppe Gentile, Alessandra Micozzi, Alessandro Pulsoni

Blood (2022) 140 (Supplement 1): 3566–3567.

https://doi.org/10.1182/blood-2022-164544

Published: 2022

Journal Articles

Venous Thromboembolism (VTE) in Patients with Hodgkin Lymphoma: Retrospective Evaluation of Throly and Khorana Risk Scores

Giovanni Manfredi Assanto, Martina Salvatori, Sara Pontecorvo, Natalia Cenfra, Gianna Maria D'elia, Giorgia Annechini, Maurizio Martelli, Alessandro Pulsoni, Ilaria Del Giudice, Antonio Chistolini

Blood (2022) 140 (Supplement 1): 12018–12019.

https://doi.org/10.1182/blood-2022-164529

Published: 2022

Journal Articles

Molecular Clustering on Ctdna May Improve Prognostic Stratification of DLBCL Patients

Blood (2022) 140 (Supplement 1): 9226–9227.

https://doi.org/10.1182/blood-2022-162416

Published: 2022

Journal Articles

Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study

Blood (2021) 138 (25): 2727–2730.

https://doi.org/10.1182/blood.2021011883

Published: 2021

Includes: Supplemental data

Journal Articles

A Comprehensive and Systematic Analysis of Minimal Residual Disease (MRD) Monitoring in Follicular Lymphoma: Results from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial

Blood (2021) 138 (Supplement 1): 41.

https://doi.org/10.1182/blood-2021-146773

Published: 2021

Journal Articles

Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'

Francesca Romana Mauro, MD PhD, Gianluigi Reda, MD, Valentina Arena, MS, Livio Trentin, MD, Marta Coscia, MD PhD, Paolo Sportoletti, MD, Luca Laurenti, MD, Gianluca Gaidano, Roberto Marasca, MD, Lorella Orsucci, MD, Roberta Murru, MD, Caterina Stelitano, Fiorella Ilariucci, MD, Donato Mannina, MD, Massimo Massaia, MD, Gian Matteo Rigolin, Lydia Scarfo, Monia Marchetti, MD, Luciano Levato, MD, Monica Tani, MD, Annalisa Arcari, MD, Gerardo Musuraca, MD, Marina Deodato, Piero Galieni, Catello Califano, MD, Daniela Gottardi, MD, Anna Marina Liberati, MD, Daniela Pietrasanta, MD, Stefano Molica, MD, Ramona Cassin, MD, Andrea Visentin, MDPhD, Candida Vitale, MDPhD, Gianfranco Lapietra, MD, Irene Della Starza, PhD, Maria Stefania De Propris, PhD, Sara Raponi, PhD, Mauro Nanni, PhD, Ilaria Del Giudice, MD PhD, Giorgia Giuliani, PhD, Marco Vignetti, MD, Anna Guarini, PhD, Francesco Albano, Antonino Neri, MD, Antonio Cuneo, MD, Robin Foà, MD

Blood (2020) 136 (Supplement 1): 47–49.

https://doi.org/10.1182/blood-2020-135922

Published: 2020

Journal Articles

Mutations of the Exportin 1 (XPO1) Gene Predict Shorter Time to First Treatment in 1092 Early Stage Chronic Lymphocytic Leukemia Patients. Α Training/Validation Study

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-136389

Published: 2020

Journal Articles

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

Alessandro Pulsoni, MD, Maria Elena Tosti, Statistician, Simone Ferrero, MD, Stefano Luminari, MD, Anna Marina Liberati, Natalia Cenfra, MD, Daniela Renzi, MD, Emanuela Zanni, MD, Carola Boccomini, MD, Andres JM Ferreri, MD, Sara Rattotti, Vittorio Ruggero Zilioli, MD, Patrizia Bernuzzi, MD, Silvia Bolis, MD, Gerardo Musuraca, MD, Luca Nassi, Tommasina Perrone, MD, Caterina Stelitano, MD, Antonella Anastasia, MD, Paolo Corradini, MD, Giovanni Partesotti, MD, Francesca Re, Emanuele Cencini, MD, Clara Mannarella, MD, Donato Mannina, MD, Anna Lia Molinari, MD, Monica Tani, MD, Giorgia Annechini, MD, Giovanni Manfredi Assanto, MD, Lavinia Grapulin, MD, Irene Della Starza, PhD, Marzia Cavalli, PhD, Lucia Anna De Novi, PhD, Elena Ciabatti, Barbara Mantoan, PhD, Anna Guarini, PhD, Luca Arcaini, Umberto Ricardi, MD, Valter Gattei, MD, Sara Galimberti, MD PhD, Marco Ladetto, MD, Ilaria Del Giudice, MD, Robin Foà, MD

Blood (2019) 134 (Supplement_1): 124.

https://doi.org/10.1182/blood-2019-123106

Published: 2019

Journal Articles

External Validation of a Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. a Campus CLL Study

Blood (2019) 134 (Supplement_1): 4308.

https://doi.org/10.1182/blood-2019-126702

Published: 2019

Journal Articles

TP53 Clonal and Subclonal Architecture in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment

Ilaria Del Giudice, Luciana Cafforio, Luca Vincenzo Cappelli, MD, Caterina Ilari, PhD, Sara Raponi, Maria Stefania De Propris, Paola Mariglia, Francesca Romana Mauro, Marco Vignetti, Anna Guarini, PhD, Robin Foà, MD

Blood (2018) 132 (Supplement 1): 3119.

https://doi.org/10.1182/blood-2018-99-114232

Published: 2018

Journal Articles

The Combination of Complex Karyotypes' Subtypes and IGHV Mutational Status Provides Prognostic and Predictive Information in Chronic Lymphocytic Leukemia

Blood (2018) 132 (Supplement 1): 1844.

https://doi.org/10.1182/blood-2018-99-114721

Published: 2018

Journal Articles

BRAF and BIRC3 Mutations Stratify a Poor Prognostic Subgroup in FCR Treated Chronic Lymphocytic Leukemia

Blood (2017) 130 (Supplement 1): 260.

https://doi.org/10.1182/blood.V130.Suppl_1.260.260

Published: 2017

Journal Articles

Early Stage Follicular Lymphoma. Predictive Role of Minimal Residual Disease (MRD) and Impact of MRD-Driven Treatment with Radiotherapy and Rituximab on Clinical Outcome

Alessandro Pulsoni, MD, Irene Della Starza, PhD, Maria Elena Tosti, statistician, Luca Vincenzo Cappelli, Giorgia Annechini, Marzia Cavalli, PhD, Lucia Anna De Novi, PhD, Gianna Maria D'Elia, Lavinia Grapulin, MD, Anna Guarini, Ilaria Del Giudice, MD PhD, Robin Foa

Blood (2016) 128 (22): 2959.

https://doi.org/10.1182/blood.V128.22.2959.2959

Published: 2016

Journal Articles

Comparative Analysis Between RQ-PCR and Digital Droplet PCR of BCL2/IGH Rearrangement in the Peripheral Blood and Bone Marrow of Early Stage Follicular Lymphoma

Marzia Cavalli, PhD, Lucia Anna De Novi, PhD, Irene Della Starza, PhD, Luca Cappelli, Vittorio Nunes, Alessandro Pulsoni, MD, Ilaria Del Giudice, MD PhD, Anna Guarini, Robin Foa

Blood (2016) 128 (22): 5308.

https://doi.org/10.1182/blood.V128.22.5308.5308

Published: 2016

Journal Articles

Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study

Blood (2015) 126 (23): 2946.

https://doi.org/10.1182/blood.V126.23.2946.2946

Published: 2015

NARROW

CD49d Expression Is Included in a Revised 4-Factor Model Predicting Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Multi-Center Real-World Experience

36-Month Follow-up Results of the Gimema ‘Veritas’ Trial of Front-Line Venetoclax and Rituximab (VenR) in Young and Fit Patients with Chronic Lymphocytic Leukemia and an Adverse Biologic Profile

MRD Monitoring By Euroclonality IGH Based NGS Approach Predicts Outcome in Follicular Lymphoma Patients Lacking a Conventional BCL2::IGH Marker: A Substudy from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial

A Snapshot of the Management of Chronic Lymphocytic Leukemia in Italy. Preliminary Analysis on over 3000 Patients Enrolled in the Gimema CLL2121 Trial

Early-Stage Follicular Lymphoma: Learnings from the Final Analysis of the Multicenter Phase II FIL (Fondazione Italiana Linfomi) “Miro” Trial, Combining Local Radiotherapy and MRD-Driven Immunotherapy

Impact of Anti-Sars-Cov-2 Monoclonal Antibodies in the Management of Patients with Lymphoma and COVID19: A Retrospective Study

Venous Thromboembolism (VTE) in Patients with Hodgkin Lymphoma: Retrospective Evaluation of Throly and Khorana Risk Scores

Molecular Clustering on Ctdna May Improve Prognostic Stratification of DLBCL Patients

Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study

A Comprehensive and Systematic Analysis of Minimal Residual Disease (MRD) Monitoring in Follicular Lymphoma: Results from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial

Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'

Mutations of the Exportin 1 (XPO1) Gene Predict Shorter Time to First Treatment in 1092 Early Stage Chronic Lymphocytic Leukemia Patients. Α Training/Validation Study

EARLY STAGE Follicular Lymphoma: First Results of the FIL "Miro" Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy

External Validation of a Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. a Campus CLL Study

TP53 Clonal and Subclonal Architecture in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment

The Combination of Complex Karyotypes' Subtypes and IGHV Mutational Status Provides Prognostic and Predictive Information in Chronic Lymphocytic Leukemia

BRAF and BIRC3 Mutations Stratify a Poor Prognostic Subgroup in FCR Treated Chronic Lymphocytic Leukemia

Early Stage Follicular Lymphoma. Predictive Role of Minimal Residual Disease (MRD) and Impact of MRD-Driven Treatment with Radiotherapy and Rituximab on Clinical Outcome

Comparative Analysis Between RQ-PCR and Digital Droplet PCR of BCL2/IGH Rearrangement in the Peripheral Blood and Bone Marrow of Early Stage Follicular Lymphoma

Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only